Pathology Analysis & Statistics in the United Kingdom, November 2014

You might be interested in: Cancer, Breast Cancer, Leukemia, more »

1-50 of about 2 400 reports

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: HER2-Positive Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023

  • $ 6 995
  • Industry report
  • September 2014
  • by Global Data

PharmaPoint: HER2-Positive Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in ...

  • Industries : Pathology
  • Countries : Germany, Spain, Italy, France, United Kingdom, World, Europe
Herceptin (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Herceptin (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • September 2014
  • by Global Data

Herceptin (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Herceptin (HER2-Positive Breast Cancer) - Forecast ...

  • Industries : Pathology
  • Countries : World, United States, Spain, Italy, France, Germany, Japan, China, United Kingdom, Europe
Perjeta (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Perjeta (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • September 2014
  • by Global Data

Perjeta (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Perjeta (HER2-Positive Breast Cancer) - Forecast ...

  • Industries : Pathology
  • Countries : Japan, World, Spain, Italy, France, Germany, China, United States, United Kingdom, Europe
Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • September 2014
  • by Global Data

Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Kadcyla (HER2-Positive Breast Cancer) - Forecast ...

  • Industries : Pathology
  • Countries : Japan, World, Spain, Italy, France, Germany, China, United States, United Kingdom, Europe
Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • September 2014
  • by Global Data

Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Tykerb (HER2-Positive Breast Cancer) - Forecast ...

  • Industries : Pathology
  • Countries : World, Spain, Italy, France, Germany, Japan, China, Europe, United States, United Kingdom
Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • September 2014
  • by Global Data

Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Neratinib (HER2-Positive Breast Cancer) - Forecast ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, China, World, United States, United Kingdom, Europe
Pulmicort (Asthma) - Forecast and Market Analysis to 2023

Pulmicort (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Pulmicort (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Pulmicort (Asthma) - Forecast and Market Analysis to 2023”. The ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Advair (Asthma) - Forecast and Market Analysis to 2023

Advair (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Advair (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Advair (Asthma) - Forecast and Market Analysis to 2023”. The asthma ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Symbicort (Asthma) - Forecast and Market Analysis to 2023

Symbicort (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Symbicort (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Symbicort (Asthma) - Forecast and Market Analysis to 2023”. The ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023

Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023”. ...

  • Industries : Pathology
  • Countries : World, Australia, Spain, Italy, France, Germany, Japan, Europe, United States, United Kingdom
Fostair (Asthma) - Forecast and Market Analysis to 2023

Fostair (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Fostair (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Fostair (Asthma) - Forecast and Market Analysis to 2023”. The asthma ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, World, United Kingdom, Europe
Xolair (Asthma) - Forecast and Market Analysis to 2023

Xolair (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Xolair (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Xolair (Asthma) - Forecast and Market Analysis to 2023”. The asthma ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Spiriva (Asthma) - Forecast and Market Analysis to 2023

Spiriva (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Spiriva (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Spiriva (Asthma) - Forecast and Market Analysis to 2023”. The asthma ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Fluticasone Furoate (Asthma) - Forecast and Market Analysis to 2023

Fluticasone Furoate (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Fluticasone Furoate (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Fluticasone Furoate (Asthma) - Forecast and Market Analysis ...

  • Industries : Pathology
  • Countries : Japan, Australia, World, Spain, Italy, France, Germany, United States, United Kingdom, Europe
Cinquil (Reslizumab) (Asthma) - Forecast and Market Analysis to 2023

Cinquil (Reslizumab) (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Cinquil (Reslizumab) (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Cinquil (Reslizumab) (Asthma) - Forecast and Market Analysis ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Bosatria (Mepolizumab) (Asthma) - Forecast and Market Analysis to 2023

Bosatria (Mepolizumab) (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Bosatria (Mepolizumab) (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Bosatria (Mepolizumab) (Asthma) - Forecast and Market ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Lebrikizumab (Asthma) - Forecast and Market Analysis to 2023

Lebrikizumab (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Lebrikizumab (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Lebrikizumab (Asthma) - Forecast and Market Analysis to 2023”. ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Benralizumab (Asthma) - Forecast and Market Analysis to 2023

Benralizumab (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Benralizumab (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Benralizumab (Asthma) - Forecast and Market Analysis to 2023”. ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Dupilumab (Asthma) - Forecast and Market Analysis to 2023

Dupilumab (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Dupilumab (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Dupilumab (Asthma) - Forecast and Market Analysis to 2023”. The ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Quilizumab (Asthma) - Forecast and Market Analysis to 2023

Quilizumab (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Quilizumab (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Quilizumab (Asthma) - Forecast and Market Analysis to 2023”. ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Tralokinumab (Asthma) - Forecast and Market Analysis to 2023

Tralokinumab (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Tralokinumab (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Tralokinumab (Asthma) - Forecast and Market Analysis to 2023”. ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
EU: Hearing Aids (Excl. Parts And Accessories) - Market Report. Analysis and Forecast to 2020

EU: Hearing Aids (Excl. Parts And Accessories) - Market Report. Analysis and Forecast to 2020

  • $ 2 161
  • Industry report
  • November 2014
  • by IndexBox Marketing

The report provides an in-depth analysis of the EU Market of Hearing Aids (Excl. Parts And Accessories). It presents the latest data of the market size and volume, domestic production, exports and imports, ...

  • Industries : Pathology
  • Countries : Europe, Czech Republic, United Kingdom, Netherlands, Luxembourg, Lithuania, World, Sweden, Spain, Slovenia, Slovakia (slovak Republic), Romania, Portugal, Poland, Malta, Latvia, Italy, Ireland, Hungary, Greece, France, Germany, Finland, Estonia, Denmark, Cyprus, Croatia, Bulgaria, Belgium, Austria
Brinzolamide  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Brinzolamide - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Company report
  • October 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

  • Industries : Pathology
  • Countries : United Kingdom, Australia, Canada, Spain, Italy, France, Germany, Japan, Europe, United States, World
Duloxetine  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Duloxetine - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Company report
  • October 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

  • Industries : Pathology
  • Countries : United Kingdom, Australia, Canada, Spain, Italy, France, Germany, Japan, Europe, United States
Sildenafil  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Sildenafil - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Company report
  • October 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

  • Industries : Pathology
  • Countries : United Kingdom, Australia, Canada, Spain, Italy, France, Germany, Japan, Europe, United States, World
Sitagliptin  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Sitagliptin - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Company report
  • October 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

  • Industries : Pathology
  • Countries : United Kingdom, Australia, Canada, Spain, Italy, France, Germany, Japan, Europe, United States
Temsirolimus  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Temsirolimus - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Company report
  • October 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

  • Industries : Pathology
  • Countries : United Kingdom, Australia, Canada, Spain, Italy, France, Germany, Japan, Europe, United States, World
Donepezil  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Donepezil - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Company report
  • October 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

  • Industries : Pathology
  • Countries : United Kingdom, Australia, Canada, Spain, Italy, France, Germany, Japan, Europe, United States, World
Irbesartan  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Irbesartan - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Company report
  • October 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

  • Industries : Pathology
  • Countries : United Kingdom, Australia, Canada, Spain, Italy, France, Germany, Japan, Europe, United States, World
Rivastigmine  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Rivastigmine - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Company report
  • October 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

  • Industries : Pathology
  • Countries : United Kingdom, Australia, Canada, Spain, Italy, France, Germany, Japan, Europe, United States, World
About 3 200 reports

Download Unlimited Documents from Trusted Public Sources

Pathology Description in the UK

  • Infection Reports
  • November 2014
    7 pages
  • Hiv  

    Hepatitis B  

    Infectious Dise...  

  • United Kingdom  

    Europe  

View report >

2 Companies

Read our Company Profiles

GlaxoSmithKline P.L.C.

United States

Johnson and Johnson

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.